marked.bio

RET inhibitor (next generation) · small molecule

lunbotinib

1 active trials, targeting RET. Not approved for any biomarker on marked.bio yet.

Also known as EP0031, A400.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
RET fusion or mutation 1 1 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of lunbotinib.

  1. Ellipses Pharma 1

Trials

1 of 1 trials shown

  1. A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

    Recruiting Phase 1/2 Ellipses Pharma Started 2022Primary completion 2027-03 NCT05443126

    lunbotinibPlatinum chemotherapypemetrexed

    Must be ≥18 years of age, with documented RET-altered NSCLC

    RET fusion or mutationNSCLC